Best eQMS for CDMOs and CMOs in 2026

CDMOs and CMOs run multi-client operations under one quality system: batch records, controlled documents, change control, deviations, and CAPA can carry both internal and client-specific scope. Each client may run an audit at any time, with their own SOPs, specifications, and acceptance criteria. The eQMS must support multi-client tagging, segregation of client-confidential records, manufacturing site standardisation, and client portals or audit-ready exports. Complere supports tenant-level segregation plus per-client tagging and metadata so the same site can serve multiple clients without leakage.

Yes. A change to a shared site procedure (e.g. cleaning SOP, environmental monitoring program) can affect multiple client products. The eQMS should support multi-product impact assessment with per-client notification, validation, and effectivity tracking. Complere’s Controlled Change module links a single change to multiple affected items (documents, equipment, processes, products) and routes review through per-product workflows where required.

Client audits cover both general site SOPs and client-specific records (batch records, deviations, CAPAs for that client’s products). The eQMS must support audit scope filtering so the auditor sees only their own records plus shared site records. Complere’s Audits module supports scoped audit plans; combined with role-based access control on records, client-confidential data stays segregated during audits.

Yes. Complere supports multi-site deployments under one tenant, with per-site role assignments, per-site document folders, and per-site reporting. Per-customer regional infrastructure means a CDMO with EU, US, and India sites can run on a tenant in the customer-selected region (data does not cross regions) while still presenting a unified quality system to clients.

CDMO sizing typically scales by site count, user count (across operations + quality + regulatory + commercial), client count, and module scope. Validation depth (full CSV pack vs templated) is often a major TCO driver since validation evidence is reviewed at every client audit. Compare 3-year TCO including validation regeneration on upgrades, client audit support overhead, and any regional licensing premiums.

A CMO (Contract Manufacturing Organisation) provides manufacturing services only — typically clinical or commercial drug substance / drug product manufacturing under client specifications. A CDMO (Contract Development and Manufacturing Organisation) provides both development services (formulation, process development, analytical method development, clinical supply manufacturing) and commercial manufacturing under one organisation. Both serve multiple clients from shared sites; both face the same eQMS requirements: multi-client segregation, per-product change control, client-audit readiness. Most modern CMOs market as CDMOs to capture earlier-stage development work.

ICH Q10 (Pharmaceutical Quality System) requires the contract giver (sponsor) and contract acceptor (CDMO / CMO) to operate under a written quality agreement defining responsibilities for quality decisions including release, change control, deviations, and CAPA. The contract acceptor’s pharmaceutical quality system must be capable of managing GMP responsibilities across the outsourced activity. The eQMS must support per-client quality agreements, per-client change-control routing, and client-visible records — without exposing other clients’ data.

EU GMP Chapter 7 (Outsourced Activities) requires that any GMP activity outsourced be the subject of a written contract between the contract giver and contract acceptor, defining responsibilities for batch certification, change management, deviation management, and ongoing audits. Both parties must hold the contract, and the contract acceptor must not subcontract further without the contract giver’s written approval. The eQMS must support contract-versioned access controls, per-client deviation and CAPA workflows, and audit-ready exports for the contract giver’s quality oversight.

CDMOs face inspections from each client’s regulatory authority (FDA, EMA, MHRA, PMDA, CDSCO) plus their own GMP inspections. Each authority audits records relevant to the products it regulates, often visiting the same site within months of each other. The eQMS must support inspection-scope filtering (auditor sees records relevant to the inspecting authority’s product), real-time export of batch records / deviations / CAPAs / audit history, and ALCOA+ data integrity demonstration. Multi-region residency matters when the inspecting authority requires data review in their jurisdiction.

A Quality Agreement (sometimes Quality Technical Agreement, QTA) is a written contract between sponsor and CDMO defining division of responsibilities for GMP activities: who approves changes, who releases batches, who investigates deviations, who handles complaints, and who reports to regulators. ICH Q10 and EU GMP Chapter 7 require it for outsourced GxP activities. The eQMS interacts by enforcing the agreement in workflow: per-client routing in change control and CAPA so the right party approves at the right step, plus audit-ready evidence of agreement adherence. Complere supports per-client workflow templates, per-client role assignments, and per-client routing in Controlled Change and CAPA.